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1. Introduction
This international consensus statement is the collaborative effort
of three medical societies representing electrophysiology in North
America, Europe, and Asian-Paciﬁc area: the Heart Rhythm Society
(HRS), the European Heart Rhythm Association (EHRA), and the Asia
Paciﬁc Heart Rhythm Society. The objective of the consensus
document is to provide clinical guidance for diagnosis, risk strati-
ﬁcation, and management of patients affected by inherited primary
arrhythmia syndromes. It summarizes the opinion of the interna-
tional writing group members based on their own experience and
on a general review of the literature with respect to the clinical data
on patients affected by channelopathies.
This document does not address the indications of genetic
testing in patients affected by inherited arrhythmias and their
family members. Diagnostic, prognostic, and therapeutic implica-
tions of the results of genetic testing are also not included in this
document because this topic has been covered by a recent
publication1 coauthored by some of the contributors of this
consensus document, and it remains the reference text on this
topic. Guidance for the evaluation of patients with idiopathic
ventricular ﬁbrillation, sudden arrhythmic death syndrome, and
sudden unexplained death in infancy, which includes genetic
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testing, are provided as these topics were not covered in the
previous consensus statement.
Developing guidance for genetic diseases requires adaptation of
the methodology adopted to prepare guidelines for clinical practice.
Documents produced by other medical societies have acknowl-
edged the need to deﬁne the criteria used to rank the strength of
recommendation for genetic diseases.2
The most obvious difference encountered for inherited diseases
is that randomized and/or blinded studies do not exist in this ﬁeld.
Therefore, most of the available data derive from registries that
have followed patients and recorded outcome information. As a
consequence, all consensus recommendations are level of evidence C
(i.e., based on experts’ opinions).
The consensus recommendations in this document use the
commonly used Class I, IIa, IIb, and III classiﬁcation and the
corresponding language: “is recommended” for Class I consensus
recommendation; “can be useful” for a Class IIa consensus recom-
mendation; “may be considered” to signify a Class IIb consensus
recommendation; “should not” or “is not recommended” for a
Class III consensus recommendation (failure to provide any addi-
tional beneﬁt and may be harmful).
Deﬁnitions of special terms used in the document
The terms used in the consensus document are deﬁned as follows:
 Syncope: In the context of inherited arrhythmogenic disorders, the
occurrence of “syncope” is an important indicator of arrhythmic
risk. Although there is no deﬁnition to differentiate a syncopal
episode caused by ventricular arrhythmias from an otherwise
unexplained syncope, in the context of this document, the term
“syncope” implies the exclusion of events that are likely due to
vasovagal events such as those occurring during abrupt postural
changes, exposure to heat and dehydration, and emotional reac-
tions to events such as blood drawing. We refer to the guidelines of
ESC and AHA/ACCF for the differential diagnoses of syncope.3,4
 Symptomatic individuals: The term “symptomatic” refers to
individuals who have experienced ventricular arrhythmias
(usually ventricular tachycardia or resuscitated ventricular ﬁbril-
lation) or syncopal episodes (see deﬁnition above). The presence
of symptoms is, in some of the channelopathies, an independent
predictor of cardiac arrest at follow-up.
 Arrhythmic events: The term refers to the occurrence of
symptomatic or asymptomatic sustained or nonsustained
spontaneous ventricular tachycardia or unexplained syncope/
resuscitated cardiac arrest.
 Concealed mutation-positive patients: This term is used to
refer to individuals without clinical symptoms or phenotype of
a channelopathy who carry the genetic defect present in
clinically affected members of the family.
Methodological aspects and instructions for the consultation of the
document
When considering the guidance from this document, it is impor-
tant to remember that there are no absolutes governing many clinical
situations. The ﬁnal judgment regarding care of a particular patient
must be made by the health-care provider and the patient in light of
all relevant circumstances. Recommendations are based on the
consensus of the writing group following the Heart Rhythm Society’s
established consensus process. It is recognized that consensus does
not mean unanimous agreement among all writing group members.
We identiﬁed the aspects of patients’ care for which a true consensus
could be found. Surveys of the entire writing group were used. The
authors received an agreement that was greater than or equal to 84%
on all recommendations; most recommendations received agree-
ment of 94% or higher.
This statement is directed to all health-care professionals who
are involved in the management of (1) individuals who survived a
cardiac arrest at a young age (usually deﬁned as o40 years) in the
absence of a clinical diagnosis of cardiac disease, despite extensive
clinical assessment; (2) family members of individuals who died
suddenly at young age with a negative autopsy; (3) in patients and
family members in whom the diagnosis of a channelopathy is
clinically possible, likely, or established; and (4) young patients
with unexplained syncope.
All members of this document writing group provided disclo-
sure statements of all relationships that might present real or
perceived conﬂicts of interest. Disclosures for all members of the
writing group are published in Appendix A.
2. Long QT Syndrome (LQTS)
Expert Consensus Recommendations on LQTS Diagnosis
1. LQTS is diagnosed:
a. In the presence of an LQTS risk score Z3.5 in the
absence of a secondary cause for QT prolongation and/or
b. In the presence of an unequivocally pathogenic
mutation in one of the LQTS genes or
c. In the presence of a corrected QT interval for heart rate
using Bazett’s formula (QTc) Z500 ms in repeated 12-
lead electrocardiogram (ECG) and in the absence of a
secondary cause for QT prolongation.
2. LQTS can be diagnosed in the presence of a QTc between 480
and 499 ms in repeated 12-lead ECGs in a patient with
unexplained syncope in the absence of a secondary cause for
QT prolongation and in the absence of a pathogenic mutation.
Expert Consensus Recommendations on LQTS Therapeutic
Interventions
Class I 1. The following lifestyle changes are recommended in
all patients with a diagnosis of LQTS:
a. Avoidance of QT-prolonging drugs (www.
qtdrugs.org)
b. Identiﬁcation and correction of electrolyte
abnormalities that may occur during diarrhea,
vomiting, metabolic conditions, or imbalanced
diets for weight loss.
2. Beta-blockers are recommended in patients with a
diagnosis of LQTS who are:
a. Asymptomatic with QTc 4470 ms and/or
b. Symptomatic for syncope or documented
ventricular tachycardia/ventricular ﬁbrillation
(VT/VF).
3. Left cardiac sympathetic denervation (LCSD) is
recommended in high-risk patients with a diagnosis
of LQTS in whom:
a. Implantable cardioverter-deﬁbrillator (ICD)
therapy is contraindicated or refused and/or
b. Beta-blockers are either not effective in
preventing syncope/arrhythmias, not
tolerated, not accepted or contraindicated.
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4. ICD implantation is recommended in patients with a
diagnosis of LQTS who are survivors of a cardiac
arrest.
5. All LQTS patients who wish to engage in competitive
sports should be referred to a clinical expert for the
evaluation of risk.
Class
IIa
6. Beta-blockers can be useful in patients with a
diagnosis of LQTS who are asymptomatic with QTc
r470 ms.
7. ICD implantation can be useful in patients with a
diagnosis of LQTS who experience recurrent
syncopal events while on beta-blocker therapy.
8. LCSD can be useful in patients with a diagnosis of
LQTS who experience breakthrough events while on
therapy with beta-blockers/ICD.
9. Sodium channel blockers can be useful, as add-on
therapy, for LQT3 patients with a QTc 4500 ms who
shorten their QTc by 440 ms following an acute oral
drug test with one of these compounds.
Class
III
10. Except under special circumstances, ICD
implantation is not indicated in asymptomatic
LQTS patients who have not been tried on beta-
blocker therapy.
Epidemiology
Patients affected by the LQTS have been identiﬁed all over the
world and in all ethnic groups. A possible exception is represented
by a paucity of cases identiﬁed among black Africans and among
African-Americans. Among Caucasians, the prevalence of LQTS has
been 1:2000 apparently healthy live births.5
Clinical manifestations
The clinical manifestations of LQTS fall under two main
categories: the arrhythmic events and the ECG aspects.
The arrhythmic events are due to runs of torsades de pointes
VT, which, according to its duration, produces syncope and—when
it deteriorates into VF—cardiac arrest or sudden death.
In ECG alterations, prolongation of the QT interval is the
hallmark of LQTS but it is not always present. Ventricular repolar-
ization is not only prolonged but often presents bizarre morpho-
logic alterations, some of which tend to be gene-speciﬁc.6
Diagnosis
The diagnosis of LQTS is mainly based on the measurement of
the QTc. When using a prolonged QTc to diagnose LQTS, one must
exclude secondary causes of QTc prolongation that can occur with
drugs, acquired cardiac conditions, electrolyte imbalance, and
unbalanced diets. A scoring system has been established, which
takes into account the age of the patient, medical and family
history, symptoms, and QTc and provides a probability of the
diagnosis of LQTS.7,8
Approximately 20%–25% of the patients with LQTS conﬁrmed
by the presence of an LQTS gene mutation may have a normal
range QTc.9,10
Risk stratiﬁcation
Individuals at the extremes of the curve, those at very high or
at very low risk, are easy to identify. For the larger group, in the
gray area, risk stratiﬁcation is difﬁcult and can be fraught with
errors in either direction. The Jervell and Lange-Nielsen syn-
drome11 and the extremely rare Timothy syndrome (LQT8)12 are
highly malignant, manifest with major arrhythmic events, and
respond poorly to therapies. Within the most common genetic
groups, speciﬁc locations, types of mutations, and degree of
mutation dysfunction are associated with different risks.
High risk is present whenever QTc 4500 ms9,13 and becomes
extremely high whenever QTc 4600 ms. Patients with two
unequivocally pathogenic variants and a QTc 4500 ms are also
at high risk. The presence of overt T-wave alternans is a direct sign
of electrical instability and calls for preventive measures. Patients
who have syncope or cardiac arrest before age 7 have a higher
probability of recurrence of arrhythmic events while on beta-
blockers.14 Patients who have syncope or cardiac arrest in the ﬁrst
year of life are at high risk for lethal events and may not be fully
protected by the traditional therapies.15,16 Patients who suffer
arrhythmic events despite being on full medical therapy are at
higher risk.
Management
Lifestyle modiﬁcations such as avoidance of strenuous exercise
and avoidance of drugs that prolong QT interval in all LQTS
patients should be routine. Participation of LQTS patients in
competitive sports is still a matter of debate among the experts.
Speciﬁc therapies available for patients with LQTS and indications
for their use are described below.
Beta-blockers
Beta-blockers are clinically indicated in LQTS, including those
with a genetic diagnosis and normal QTc, unless there is a
contraindication such as active asthma.14,15 Although studies are
not available to deﬁne the most effective dosage, full dosing for
age and weight, if tolerated, is recommended. Abrupt discontinua-
tion of beta-blockers should be avoided as this may increase the
risk of exacerbation.
ICD (Figure 1)
ICD therapy is indicated in LQTS patients who are resuscitated
from cardiac arrest.17 ICD is often favored in patients with LQTS-
related syncope who also receive beta-blockers.18 Prophylactic ICD
therapy should be considered in very high risk patients. ICD
therapy has lifetime implications, complications are not infre-
quent, especially in the younger age group, and risk/beneﬁt
considerations should be carefully considered before initiating this
invasive therapy.19,20
We suggest that ICD therapy not be used as ﬁrst-line therapy in
an asymptomatic LQTS patient; beta-blockers remain the ﬁrst-line
therapy in LQTS patients. However, an ICD may be considered in
those patients who are deemed to be at very high risk, especially
those with a contraindication to beta-blocker therapy.
Whenever ICD therapy is chosen, thoughtful programming (in
particular to prevent inappropriate shocks) is pertinent and
usually requires a VF-only zone, with a cutoff rate greater than
220–240 bpm.
LCSD
This procedure is often effective in reducing the probability for
arrhythmic events in high-risk patients, including those who are
intolerant of or refractory to beta-blockers alone.21
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3. Brugada Syndrome (BrS)
Expert Consensus Recommendations on BrS Diagnosis
1. BrS is diagnosed in patients with ST-segment elevation with
type I morphology Z2 mm in Z1 lead among the right
precordial leads V1,V2 positioned in the 2nd, 3rd, or 4th
intercostal space occurring either spontaneously or after
provocative drug test with intravenous administration of Class
I antiarrhythmic drugs.
2. BrS is diagnosed in patients with type 2 or type 3 ST-segment
elevation in Z1 lead among the right precordial leads V1,V2
positioned in the 2nd, 3rd, or 4th intercostal space when a
provocative drug test with intravenous administration of Class
I antiarrhythmic drugs induces a type I ECG morphology.
Expert Consensus Recommendations on BrS Therapeutic
Interventions
Class I 1. The following lifestyle changes are recommended in
all patients with diagnosis of BrS:
a. Avoidance of drugs that may induce or
aggravate ST-segment elevation in right
precordial leads (e.g., Brugadadrugs.org)
b. Avoidance of excessive alcohol intake
c. Immediate treatment of fever with
antipyretic drugs.
2. ICD implantation is recommended in patients with a
diagnosis of BrS who:
a. Are survivors of a cardiac arrest and/or
b. Have documented spontaneous sustained VT
with or without syncope.
Class
IIa
3. ICD implantation can be useful in patients with a
spontaneous diagnostic type I ECG who have a
history of syncope judged to be likely caused by
ventricular arrhythmias.
4. Quinidine can be useful in patients with a diagnosis
of BrS and history of arrhythmic storms deﬁned as
more than two episodes of VT/VF in 24 hours.
5. Quinidine can be useful in patients with a diagnosis
of BrS who:
a. Qualify for an ICD but present a
contraindication to the ICD or refuse it and/or
b. Have a history of documented
supraventricular arrhythmias that require
treatment.
6. Isoproterenol infusion can be useful in suppressing
arrhythmic storms in BrS patients.
Class
IIb
7. ICD implantation may be considered in patients
with a diagnosis of BrS who develop VF during
programmed electrical stimulation (inducible
patients).
8. Quinidine may be considered in asymptomatic
patients with a diagnosis of BrS with a spontaneous
type I ECG.
9. Catheter ablation may be considered in patients
with a diagnosis of BrS and history of arrhythmic
storms or repeated appropriate ICD shocks.
Class
III
10. ICD implantation is not indicated in asymptomatic
BrS patients with a drug-induced type I ECG and on
the basis of a family history of sudden cardiac death
(SCD) alone.
Epidemiology
No precise data are available on the epidemiology of BrS.
However, its prevalence is much higher in Asian and Southeast
Asian countries, especially Thailand, The Philippines, and Japan,
reaching 0.5–1 per 1000.22 BrS is 8–10 times more prevalent in
men than in women.22
Genetic basis
Inheritance of BrS occurs via an autosomal dominant mode of
transmission. Twelve responsible genes have been reported so
far.23 In all 12 genotypes, either a decrease in the inward sodium or
calcium current or an increase in one of the outward potassium
currents has been shown to be associated with the BrS phenotype.
Clinical manifestations
Symptoms associated with BrS include VF or aborted SCD
(more often at night than during the day), syncope, nocturnal
agonal respiration, palpitations, and chest discomfort. These
symptoms often occur during rest or sleep, during a febrile state,
or with vagotonic conditions, but rarely during exercise.
Diagnosis
BrS is deﬁnitively diagnosed when a type I ST-segment eleva-
tion is observed either spontaneously or after intravenous admin-
istration of a sodium channel blocking agent (ajmaline, ﬂecainide,
pilsicainde, or procainamide) in at least one right precordial lead
(V1 and V2),24 which are placed in a standard or a superior position
(up to the 2nd intercostal space).25,26
Figure 1. Consensus recommendations for ICDs in patients diagnosed with long QT
syndrome.
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Prognosis and risk stratiﬁcation
Since the ﬁrst reporting, the reported annual rate of events has
decreased.27–34
Several clinical variables have been demonstrated to predict a
worse outcome in patients with BrS. The high risk of recurrence of
cardiac arrest is seen among patients who have survived a ﬁrst VF.
These patients should be protected with an ICD, irrespective of the
presence of other risk factors.22
Most studies have concurrently agreed on the evidence that the
presence of syncopal episodes in patients with a spontaneous type
I ECG at baseline (without conditions known to unmask the
signature sign, i.e., drugs and fever) have high risk of cardiac
arrhythmic events at follow-up.27–36
Among other risk stratiﬁcation indicators, the presence of
fragmented QRS27,37 and an effective refractory period below
200 ms27,38 have been recently proposed. Male sex has consis-
tently been shown to be associated with more arrhythmic
events.39
Although large registries agree that electrophysiological study
(EPS) inducibility is greatest among BrS patients with previous
sudden death or syncope,31,32 there is no consensus on the value
of the EPS in predicting outcome.
Therapeutic options and recommendations for BrS patients
ICD (Figure 2)
The only proven effective therapeutic strategy for the preven-
tion of SCD in BrS patients is the ICD. It is important to remark that
ICDs are not free from several disadvantages, especially in the
group of patients who are active young individuals who will
require multiple device replacements during their lifetime.
Asymptomatic BrS patients do not qualify for an ICD as their risk
for life-threatening events is very low.23
Pharmacological treatment in BrS
Isoproterenol (which increases the L-type calcium current) has
proved to be useful for the treatment of electrical storm in BrS,40
but controlled data on its therapeutic role are not available.
Quinidine, a Class Ia antiarrhythmic drug with transient out-
ward potassium current and rapid delayed rectiﬁer current blocker
effects, has been shown to prevent the induction of VF and
suppress spontaneous ventricular arrhythmias in a clinical setting.
Radiofrequency catheter ablation in BrS
After the demonstration that VF events were triggered by
ventricular ectopy of similar morphology, radiofrequency ablation
of ventricular ectopy has been postulated as a therapeutic
approach in BrS patients. Few anecdotal cases in high-risk BrS
implanted with an ICD have shown no short-term recurrence of
VF, syncope, or SCD.41–44 Nademanee et al45 have presented the
ﬁrst series showing that electrical epicardial substrate ablation in
the right ventricular outﬂow tract can prevent VF inducibility in a
high-risk population.
4. Catecholaminergic Polymorphic Ventricular Tachycardia
(CPVT)
Expert Consensus Recommendations on CPVT Diagnosis
1. CPVT is diagnosed in the presence of a structurally normal
heart, normal ECG, and unexplained exercise or
catecholamine-induced bidirectional VT or polymorphic
ventricular premature beats (VPBs) or VT in an individual
younger than 40 years.
2. CPVT is diagnosed in patients (index case or family member)
who have a pathogenic mutation.
3. CPVT is diagnosed in family members of a CPVT index case
with a normal heart who manifest exercise-induced
premature ventricular contractions or bidirectional/
polymorphic VT.
4. CPVT can be diagnosed in the presence of a structurally
normal heart and coronary arteries, normal ECG, and
unexplained exercise or catecholamine-induced bidirectional
VT or polymorphic VPBs or VT in an individual older than
40 years.
Expert Consensus Recommendations on CPVT Therapeutic
Interventions
Class I 1. The following lifestyle changes are recommended in
all patients with a diagnosis of CPVT:
a. Limit/avoid competitive sports
b. Limit/avoid strenuous exercise
c. Limit exposure to stressful environments.
2. Beta-blockers are recommended in all symptomatic
patients with a diagnosis of CPVT.
3. ICD implantation is recommended in patients with a
diagnosis of CPVT who experience cardiac arrest,
recurrent syncope or polymorphic/bidirectional VT
despite optimal medical management, and/or LCSD.
Class
IIa
4. Flecainide can be a useful addition to beta-blockers
in patients with a diagnosis of CPVT who experience
recurrent syncope or polymorphic/bidirectional VT
while on beta-blockers.
Figure 2. Consensus recommendations for ICDs in patients diagnosed with Brugada
syndrome.
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5. Beta-blockers can be useful in carriers of a
pathogenic CPVT mutation without clinical
manifestations of CPVT (concealed mutation-
positive patients).
Class
IIb
6. LCSDmay be considered in patients with a diagnosis
of CPVT who experience recurrent syncope or
polymorphic/bidirectional VT/several appropriate
ICD shocks while on beta-blockers and in patients
who are intolerant or with contraindication to beta-
blockers.
Class
III
7. ICD as a stand-alone therapy is not indicated in an
asymptomatic patient with a diagnosis of CPVT.
8. Programmed electrical stimulation is not indicated
in CPVT patients.
Introduction
CPVT is a rare arrhythmogenic disorder characterized by
adrenergic-induced bidirectional and polymorphic VT.46,47
Epidemiology
The prevalence of the disease could be as high as 0.1:1000.
However, the number is a rough estimate and is not derived from a
systematic assessment in the population.
Genetic variants
Two types of CPVT have been identiﬁed: an autosomal dominant
form, resulting from mutations in the gene encoding for the cardiac
ryanodine receptor (RyR2)48,49 known as CPVT1; and a less common
autosomal recessive form, resulting from mutations in the gene for
cardiac calsequestrin (CASQ2)50,51 known as CPVT2. Altogether
mutations in RyR252 and CASQ2 are found in only 60% of the CPVT
patients,1 suggesting that other genes may be involved in CPVT. In
addition, mutations in KCNJ2 (also causing ATS [LQTS7]), Ank2,
TRDN, and CALM1) have been associated with CPVT.53-57
Clinical manifestations
The ﬁrst clinical episode often manifests in the ﬁrst or second
decade of life and is usually prompted by physical activity or
emotional stress.47,58,59 When the fainting episode is associated
with seizure-like activity, it may be attributed to a neurologic
diagnosis, thus causing delay in the diagnosis of CPVT. A family
history of exercise-related syncope, seizure, or sudden death is
reported in 30% of the patients and may help directing diagnosis
toward CPVT.
Diagnosis
CPVT patients present a normal resting ECG occasionally with a
lower than normal heart rate.47,60 When patients start exercising
ventricular ectopy develops, increasing in complexity as the heart
rate increases. Indeed, initially monomorphic VPBs appear and
they may be followed by polymorphic VPBs and bidirectional or
polymorphic VT.
Risk stratiﬁcation
There are not many indicators of risk of adverse outcome in
CPVT. The occurrence of cardiac arrest before diagnosis, but not
the occurrence of syncope, is associated with a higher risk of
arrhythmic episodes at follow-up.60 Similarly, diagnosis in child-
hood is a predictor of adverse outcome. After diagnosis, the lack of
beta-blocker therapy and the use of beta-blockers other than
nadolol are independent predictors for arrhythmic events.60 Also,
the persistence of complex ectopy in exercise tests is a marker for
worse outcome.60
Management
Beta-blockers
The ﬁrst-line therapeutic option for patients with CPVT is beta-
blockers without intrinsic sympathomimetic activity combined
with exercise restriction.
Nadolol being a long-acting drug is preferred for prophylactic
therapy and has been found to be clinically effective. The dosage
used is usually high (1–2 mg/kg), with the necessity of a faultless
compliance to the therapy. The annual rate of arrhythmic events
on beta-blockers ranges between 11% per year and 3% per year (27
% over 8 years).60 Larger groups of CPVT probands are needed to
address the issue of beta-blocker efﬁcacy in CPVT. As nadolol is not
available in several countries, it may be suggested that other
nonselective beta-blockers are equally effective (i.e., propranolol).
Holter recordings and exercise tests should be repeated periodi-
cally to assure that the degree of sinus tachycardia that precedes
the onset of arrhythmias is known so that in daily life it can be
avoided as much as possible. Moreover, to prevent non-
compliance-related SCD, it is crucial to alert the patients of the
importance of adherence to therapy to preempt life-threatening
events.
ICD
An ICD should be considered in CPVT patients who do not
respond to an optimal medical management and when LCSD is not
possible. All efforts should be made to ensure that patients with an
ICD also have an optimal medical treatment.61,62 In patients who
have experienced an aborted cardiac arrest before the initiation of
therapy, beta-blockers or beta-blockers and ﬂecainide should be
started and ICD implanted.
Implantation of an ICD is a technical challenge in pediatric
patients and problems such as inappropriate shocks, proarrhyth-
mic effects of the ICD, and the need for a lifetime protection
requiring multiple reinterventions should be addressed when the
decision is taken. Painful shocks by ICD can increase the sympa-
thetic tone and trigger further arrhythmias, leading to a malignant
cycle of ICD shocks and even death. Because of this, the ICD should
be programmed with long delays before shock delivery and high
cutoff rates.
Verapamil
Verapamil has been shown to be beneﬁcial in some CPVT
patients by reducing the ventricular arrhythmia burden on top of
beta-blocker therapy during a short-term follow-up period,63,64
though its long-term effect remains controversial.
Flecainide
Flecainide reduces signiﬁcantly the ventricular arrhythmia
burden in a limited number of CPVT patients.65,66 A larger study
is required to fully elucidate the effect of the drug, but ﬂecainide
should now be regarded as the ﬁrst addition to beta-blockers
when control of arrhythmias seems incomplete.
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LCSD
Small series have been published reporting signiﬁcant results
of LCSD on arrhythmic events.67–73 Although the short-term
results seem encouraging, more data with a long-term follow-up
are needed.
Catheter ablation
Catheter ablation of the bidirectional VPBs that trigger VF may
become an adjunctive therapy in patients with refractory CPVT.
However, the published experience is very limited and is therefore
not discussed in the recommendation.74
Evaluation of family members
Family screening (siblings and parents) by clinical evaluation
and genetic testing (when a mutation has been detected) is
mandatory to identify undiagnosed patients and asymptomatic
carriers who are at risk of arrhythmic events and should be
treated. It is suggested that genetically positive family members
should receive beta-blockers even after a negative exercise
test.60,75
5. Short QT Syndrome (SQTS)
Expert Consensus Recommendations on SQTS Diagnosis
1. SQTS is diagnosed in the presence of a QTc r330 ms.
2. SQTS can be diagnosed in the presence of a QTc o360 ms and
one or more of the following: a pathogenic mutation, family
history of SQTS, family history of sudden death at age r40
years, and survival of a VT/VF episode in the absence of heart
disease.
Expert Consensus Recommendations on SQTS Therapeutic
Interventions
Class I 1. ICD implantation is recommended in symptomatic
patients with a diagnosis of SQTS who:
a. Are survivors of a cardiac arrest and/or
b. Have documented spontaneous sustained VT
with or without syncope.
Class
IIb
2. ICD implantation may be considered in
asymptomatic patients with a diagnosis of SQTS and
a family history of SCD.
3. Quinidine may be considered in asymptomatic
patients with a diagnosis of SQTS and a family
history of SCD.
4. Sotalol may be considered in asymptomatic patients
with a diagnosis of SQTS and a family history of SCD.
Epidemiology and genetic bases
One of the rarer cardiac channelopathies is the SQTS. Gussak et al76
were the ﬁrst to suggest an association with atrial ﬁbrillation and VF
(i.e., SCD). With more case reports halfway through the ﬁrst decade of
this century, this association became clearer,77–79 but more than 10
years after the ﬁrst description, the number of patients reported is
small, underlining the fact that the disease entity is indeed rare.80 Until
now, DNA variants in 3 potassium channel genes—KCNH2, KCNQ1, and
KCNJ2—have been described to associate with SQTS78,79,81; interest-
ingly, mutations in these three genes are also linked with three
variants of LQTS: LQT1, LQT2, and LQT7, respectively.
Clinical diagnosis
The diagnosis of SQTS is still a matter of debate. A major point
of discussion in the deﬁnition of diagnostic criteria is represented
by the cutoff value at the lower end of the QTc that should be used
to diagnose the disease. The QTc should be calculated avoiding
tachycardia and bradycardia to prevent the use of Bazett’s formula
at rates at which its correction is not linear and may lead to the
underestimation or overestimation of QTc values.
This group has reached a consensus that a cutoff value of r330
ms should be used for the diagnosis.
Risk stratiﬁcation and treatment
Therapeutic management using ICDs is undisputed in SQTS
patients who have experienced sustained VT/VF episodes.80
Appropriate programming of the ICD is needed to prevent inap-
propriate ICD shocks from T-wave oversensing due to tall T waves.
Quinidine seems to be an effective alternative due to the QT-
prolonging action. Other drugs, including Class III drugs, such as
sotalol, are not effective in prolonging the QTc in SQT1 patients,82
but may be effective in other subtypes.
The optimal strategy for the primary prevention of cardiac
arrest in SQTS is not clear, given the lack of independent risk
factors for cardiac arrest.
There are certainly no data to support the implantation of an
ICD in asymptomatic patients with SQTS. An ICD might be
considered in SQTS patients with a strong family history of SCD
and evidence for abbreviated QTc in at least some of the victims.
6. Early Repolarization (ER)
Expert Consensus Recommendations on ER Diagnosis
1. ER syndrome is diagnosed in the presence of J-point elevation
Z1 mm in Z2 contiguous inferior and/or lateral leads of a
standard 12-lead ECG in a patient resuscitated from otherwise
unexplained VF/polymorphic VT.
2. ER syndrome can be diagnosed in a SCD victim with a
negative autopsy and medical chart review, with a previous
ECG demonstrating J-point elevation Z1 mm in Z2
contiguous inferior and/or lateral leads of a standard 12-
lead ECG.
3. ER pattern can be diagnosed in the presence of J-point
elevation Z1 mm in Z2 contiguous inferior and/or lateral
leads of a standard 12-lead ECG.
Expert Consensus Recommendations on ER Therapeutic
Interventions
Class I 1. ICD implantation is recommended in patients with a
diagnosis of ER syndrome who have survived a
cardiac arrest.
Class
IIa
2. Isoproterenol infusion can be useful in suppressing
electrical storms in patients with a diagnosis of ER
syndrome.
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3. Quinidine in addition to an ICD can be useful for
secondary prevention of VF in patients with a
diagnosis of ER syndrome.
Class
IIb
4. ICD implantationmay be considered in symptomatic
family members of ER syndrome patients with a
history of syncope in the presence of ST-segment
elevation 41 mm in two or more inferior or
lateral leads.
5. ICD implantation may be considered in
asymptomatic individuals who demonstrate a high-
risk ER ECG pattern (high J-wave amplitude,
horizontal/descending ST-segment) in the presence
of a strong family history of juvenile unexplained
sudden death with or without a pathogenic
mutation.
Class
III
6. ICD implantation is not recommended in asympto-
matic patients with an isolated ER ECG pattern.
Deﬁnition and epidemiology
ER is a common ECG pattern characterized by J-point and
ST-segment elevation in two or more contiguous leads. The pre-
sence of an ER pattern in the precordial leads has been considered a
benign phenomenon, but recently its presence in the inferior and/or
lateral leads has been associated with idiopathic ventricular ﬁbrilla-
tion (IVF) in case-control studies (ER syndrome).83–88
The ER ECG pattern (41 mm) in the inferior/lateral leads
occurs in 1%–13% of the general population and in 15%–70% of the
IVF cases.83–91 In the pediatric age group, it is even more prevalent.
Male sex is strongly associated with the ER ECG pattern, since
more than 70% of the subjects with ER are men. The ER pattern is
more common in young physically active individuals, athletes, and
African-Americans.92 There is an increased prevalence of ER
reported in Southeast Asians.89
Clinical diagnosis
Patients with the ER pattern on the 12-lead ECG who have been
resuscitated from an ECG-documented episode of IVF and/or
polymorphic VT are those diagnosed with ER syndrome. Similarly,
SCD victims with a negative autopsy with an archived ECG
showing the ER pattern are also diagnosed with ER syndrome
when evidence of other diagnoses have been excluded.
At this stage of our understanding of ER, there is an unusual
dilemma in which the ECG pattern is highly prevalent, the inheritance
is not clearly monogenic in most cases, and the genetic substrate is not
clearly deﬁned. For this reason, we have chosen not to label family
members with the ER pattern as ER syndrome patients, pending a
better understanding of their risk. High-risk features including extent
of family history of SCD, arrhythmic syncope, and amplitude and
morphology of the ER pattern may lead to consideration of a
prophylactic ICD in conjunction with review by an expert center with
a focus on inherited arrhythmias. Asymptomatic individuals with the
ER pattern on ECG with a mutation considered pathogenic for ER as
well as family members of a patient diagnosed with ER syndromewho
present with a diagnostic ECG may be affected by the disease.
Genetic variants
Familial ER has been reported to have an autosomal dominant
inheritance pattern with incomplete penetrance. Two independent
population-based studies have also suggested some degree of
inheritance of the ER patterns in the general population,93,94 but
the familial inheritance of malignant ER patterns has not been
clearly demonstrated.83
Clinical manifestations
Life-threatening arrhythmias are often the ﬁrst and unexpected
manifestation of ER syndrome. The majority of population-based
studies have shown that subjects with ER in the inferior leads are
at a higher risk of all-cause mortality, cardiac mortality, and
especially unexpected sudden death,89–91,95 though some excep-
tions have been reported.96
Risk stratiﬁcation
The magnitude of the J-point elevation may have prognostic
signiﬁcance. Either slurred or notched J-point elevation Z0.2 mV
is relatively rare in the general population but appears to be
associated with an increased risk.91 A horizontal or descending ST-
segment elevation following J-point elevation is associated with a
worse outcome in the general population.97 This observation has
been very helpful in distinguishing IVF patients from matched
controls and is a key aid in clinical decision making.98
Management
The clinical implications of the observation of an ER pattern in
the ECG of an asymptomatic subject are not clear. The presence of
ER is associated with three times the risk of developing VF, but the
overall risk is still negligible, considering the rarity of VF in the
general population.88,99
Electrical storm is relatively common after ICD implantation in
patients with ER syndrome.100,101 Case series evidence supports
the acute use of isoproterenol for the suppression of recurrent
VF and quinidine for long-term suppression.100,101 Isoproterenol
is typically initiated at 1.0 μg/min, targeting a 20% increase in
heart rate or an absolute heart rate 490 bpm, titrated to
hemodynamic response and suppression of recurrent ventricular
arrhythmia.
Screening of family members
No recommendations can be given to screen the families of
individuals with an asymptomatic ER pattern.
7. Progressive Cardiac Conduction Disease (PCCD)
Expert Consensus Recommendations on PCCD Diagnosis
1. PCCD is diagnosed in the presence of unexplained progressive
conduction abnormalities in young (o50 years) individuals
with structurally normal hearts in the absence of skeletal
myopathies, especially if there is a family history of PCCD.
Expert Consensus Recommendations on PCCD Therapeutic
Interventions
Class I 1. Pacemaker implantation is recommended in patients
with a diagnosis of PCCD and the presence of:
a. Intermittent or permanent third-degree or
high-grade atrioventricular (AV) block or
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b. Symptomatic Mobitz I or II second-degree
AV block.
Class
IIa
2. Pacemaker implantation can be useful in patients
with a diagnosis of PCCD and the presence of
bifascicular block with or without ﬁrst-degree
AV block.
3. ICD implantation can be useful in adult patients
diagnosed with PCCD with a mutation in the Lamin
A/C gene with left ventricular dysfunction and/or
nonsustained VT.
Introduction
PCCD is a heterogeneous disorder of unclear etiology, which
can be serious and potentially life-threatening. Its underlying
mechanism can be either functional or structural or there can be
overlap between these two mechanisms.102 The most frequent
form of PCCD is a degenerative form called Lenegre-Lev disease.
The mechanism of PCCD with structural abnormality is considered
as a primary degenerative disease or an exaggerated aging process,
with sclerosis principally affecting the conduction tissue.103 Aging
itself is suggested to play a critical role in PCCD, meaning that at
every age, conduction abnormalities are more outspoken than
expected based on age alone.
Both familial PCCD with a structurally normal heart (hereby
deﬁned as “isolated PCCD”) and familial PCCD associated with
dilated cardiomyopathy will be discussed.
Genetic variants
The discovery of gene mutations that are causally involved in
inherited PCCD is relatively recent.102 Common PCCD-associated
genes (deﬁned as genes with causative mutation in more than 5%
of the affected individuals1) are SCN5A and TRPM4 for PCCD
occurring in the structurally intact heart104 and LMNA for PCCD
associated with heart failure.1
PCCD and structurally normal heart
Mutations in the SCN5A gene cause the majority of familial
PCCD and often cause a combined phenotype with BrS.103 Subtle
structural abnormalities, mainly ﬁbrosis, are present in SCN5A
mutation-positive subjects. Recently, mutations in the transient
receptor potential channel, subfamily M(elastatine), member 4
(TRPM4) Ca2þ-activated channel gene were reported in patients
with PCCD105 and are estimated to account for a signiﬁcant portion
of inherited forms of right bundle branch block (25%) or AV block
(10%).1
PCCD and structurally abnormal heart
When PCCD is accompanied by the presence of concomitant
congenital heart disease, mutations in early cardiac transcription
factor genes, such as Nkx2.5 or GATA4, are more likely. Mutations
in Nkx2.5 or TBX5, genes involved in the regulation of heart
development, are associated with structural congenital heart
defects, such as septal defects.103
PCCD may also precede the development of dilated cardiomyo-
pathy. Mutations in the LMNA gene encoding Lamin A/C were
found to be causally involved in Emery-Dreifus muscular
dystrophy as well as in families with dilated cardiomyopathies
and severe PCCD without skeletal muscle involvement.102,103,106
Clinical manifestations
PCCD can be seen by a prolonged P-wave duration, PR interval,
and QRS widening with axis deviation on the surface ECG, which
may progress over time as an age-dependent penetrance. In
isolated forms of PCCD, there are typically no extracardiac man-
ifestations. In nonisolated forms of PCCD, congenital heart disease,
cardiomyopathy, or extracardiac manifestations are present. Phe-
notypic expression of mutations may vary from individual to
individual and has, among others, an age-dependent onset.1
In patients with mutations in the LMNA gene and PCCD, the AV
node and specialized conduction system are progressively
replaced by ﬁbrofatty tissue and patients are at risk for premature
SCD.106,107 In addition to conduction abnormalities, most adult
patients with LMNA mutations have AV conduction disturbances
and atrial and ventricular arrhythmias.108 Heart failure is a
common phenotypic feature in families with cardiac manifesta-
tions of LMNA disease.109,110 The occurrence of tachyarrhythmia
and sudden death is expected to be more frequent in PCCD
patients that carry loss-of-function SCN5A mutations, a disease
entity comparable with SCN5A-associated BrS.102
Diagnosis
The diagnosis of PCCD in an index patient is based on clinical
data including history, family history, and 12-lead ECG. The
potential presence of congenital heart disease and/or cardiomyo-
pathy must be investigated by 2-D echocardiography or other
imaging modalities, such as cardiac magnetic resonance imaging
(MRI). Early-onset PCCD in the absence of structural heart disease
should prompt consideration of PCCD genetic testing, particularly
if there is a positive family history of conduction abnormalities,
pacemaker implants, or sudden death.1
(Targeted) genetic testing may be considered as part of the
diagnostic evaluation for patients with either isolated PCCD or
PCCD with concomitant structural heart disease, especially when
there is documentation of a positive family history of PCCD.1
Risk stratiﬁcation
Screening for underlying cardiovascular manifestations with a
resting 12-lead ECG, Holter, or 2-D echocardiogram is recom-
mended, independent of symptom status. Patients with ﬁrst-
degree AV block in association with bifascicular block and sympto-
matic advanced AV block have a substantial incidence of sudden
death. In the presence of permanent or transient third-degree AV
block, syncope is associated with an increased incidence of sudden
death regardless of EPS results.111 Based on this evidence in
patients with PCCD diagnosis, pacemaker implant may be indi-
cated even in individuals with bifascicular block and ﬁrst-degree
AV block, thus representing an exception to the recommendation
set by international guidelines for patients who have this pheno-
type in all the other clinical conditions.
Patients with LMNA mutations may experience malignant
arrhythmias and SCD despite pacemaker implantation.106 ICD
therapy is therefore warranted at an early stage; a risk stratiﬁca-
tion scheme has recently been proposed.112
Management
Once cardiac involvement occurs, particularly with muscular
dystrophies, the clinician should maintain a low threshold for
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investigating symptoms or ECG ﬁndings to determine the need for
EPS, pacemaker, or ICD implantation.
Asymptomatic family members who are positive for the family’s
PCCD-associated mutation should be prospectively followed for the
early development of PCCD-related symptoms, deterioration of
cardiac conduction, and beginning signs and symptoms of heart
failure. In addition, medications with conduction-slowing proper-
ties should be restricted and fever, an aggravating trigger in
individuals with SCN5Amutations, should be preemptively treated.1
Screening of family members
Cascade family screening is useful in families with mutation-
positive PCCD. When a clinical diagnosis of PCCD is established in
an index case, a careful clinical investigation of ﬁrst-degree family
members is necessary. Genotyping of family relatives is done after
mutation identiﬁcation in the index cases and may be useful to
exclude the presence or development of PCCD.
8. Unexplained Cardiac Arrest: Idiopathic VF
Expert Consensus Recommendations on IVF Diagnosis
1. IVF is diagnosed in a resuscitated cardiac arrest victim,
preferably with documentation of VF, in whom known cardiac,
respiratory, metabolic, and toxicological etiologies have been
excluded through clinical evaluation.
Expert Consensus Recommendations on IVF Evaluation
Class
IIa
1. Genetic testing in IVF can be useful when there is a
suspicion of a speciﬁc genetic disease following clinical
evaluation of the IVF patient and/or family members.
Class
III
2. Genetic screening of a large panel of genes in IVF
patients in whom there is no suspicion of an
inherited arrhythmogenic disease after clinical
evaluation should not be performed.
Expert Consensus Recommendations on IVF Therapeutic
Interventions
Class I 1. ICD implantation is recommended in patients with a
diagnosis of IVF.
Class
IIb
2. Antiarrhythmic therapy with quinidine,
programmed electrical stimulation guided or
empirical, may be considered in patients with a
diagnosis of IVF in conjunction with ICD
implantation or when ICD implantation is
contraindicated or refused.
3. Ablation of Purkinje potentials may be considered in
patients with a diagnosis of IVF presenting with
uniform morphology premature ventricular
contractions in conjunction with ICD implantation
or when ICD implantation is contraindicated or
refused.
4. If a ﬁrst-degree relative of an IVF victim presents
with unexplained syncope and no identiﬁable
phenotype following thorough investigation, then
after careful counseling an ICD implant may be
considered.
Expert Consensus Recommendations on IVF Evaluation of Family
Members
Class I 1. Evaluation of ﬁrst-degree relatives of all IVF victims
with resting ECG, exercise stress testing, and
echocardiography is recommended. Assessment of
ﬁrst-degree relatives with history of palpitations,
arrhythmias, or syncope should be prioritized.
2. Follow-up clinical assessment is indicated in young
family members of IVF victims who may manifest
symptoms and/or signs of the disease at an older age
and in all family members whenever additional sudden
unexplained death syndrome (SUDS) or sudden
unexplained death in infancy (SUDI) events occur.
Class
IIa
3. Evaluation of ﬁrst-degree relatives of IVF victims
with Holter and signal-averaged ECGs, cardiac MRI,
and provocative testing with Class Ic antiarrhythmic
drugs can be useful.
Class
IIb
4. Evaluation of ﬁrst-degree relatives of IVF victims
with epinephrine infusion may be considered.
Deﬁnition
When individuals survive a cardiac arrest, we are able to
investigate and treat them for the underlying cause. The term
“idiopathic ventricular ﬁbrillation” (IVF) is used when the cardiac
arrest remains unexplained despite this investigation. In 1992, the
hypothesis was advanced that concealed inherited forms of
arrhythmogenic disorders could underlie IVF.113
Diagnosis
IVF is diagnosed by the exclusion through clinical evaluation of
known cardiac, respiratory, metabolic, and toxicological etiologies
that may lead to cardiac arrest. Ideally, VF should be documented.
Management
In IVF, as there is by deﬁnition no evidence for pathogenesis,
management is empirical and most patients are advised to
undergo an ICD implant. Unfortunately, the natural history of IVF
is poorly deﬁned and recurrence of arrhythmic events among IVF
patients is not consistent among different studies.114–116
Screening of family members
Experience of investigating blood relatives of IVF survivors is
limited. A noninvasive diagnostic protocol similar to that utilized
in SUDS families may be employed (see Section 9). As with families
of SUDS victims, it is reasonable that relatives of IVF survivors who
are obligate carriers or have ominous symptoms such as cardiac
syncope should be prioritized for evaluation. In families with IVF,
young family members may require periodic reassessment even
if the initial assessment is normal as young patients may only
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become cognizant of symptoms at an older age and certain
diseases have age-related penetrance. Repeated evaluations
should occur if family members become symptomatic or addi-
tional suspicious sudden deaths are identiﬁed in the family.
9. Unexplained Sudden Cardiac Death: Sudden Unexplained
Death Syndrome (SUDS) and Sudden Unexplained Death in
Infancy (SUDI)
Expert Consensus Recommendations on SUDS Diagnosis
1. It is recommended that an unexplained sudden death
occurring in an individual older than 1 year of age is known as
“sudden unexplained death syndrome” (SUDS).
2. It is recommended that a SUDS death with negative
pathological and toxicological assessment is termed “sudden
arrhythmic death syndrome” (SADS).
Expert Consensus Recommendations on SUDS Evaluation
Class I 1. It is recommended that personal/family history and
circumstances of the sudden death are collected for
all SUDS victims.
2. It is recommended that all sudden death victims
diagnosed with SUDS undergo expert cardiac
pathology to rule out the presence of microscopic
indicators of structural heart disease.
3. Collection of blood and/or suitable tissue for
molecular autopsy/postmortem genetic testing is
recommended in all SUDS victims.
Class
IIa
4. An arrhythmia syndrome-focused molecular
autopsy/postmortem genetic testing can be useful
for all SUDS victims.
Expert Consensus Recommendations on SUDS Therapeutic
Interventions
Class I 1. Genetic screening of the ﬁrst-degree relatives of a
SUDS victim is recommended whenever a
pathogenic mutation in a gene associated with an
increased risk of sudden death is identiﬁed by
molecular autopsy in the SUDS victim.
2. Evaluation of ﬁrst-degree blood relatives of all SUDS
victims with resting ECG with high right ventricular
leads, exercise stress testing, and echocardiography
is recommended. Assessment of obligate carriers
and relatives with a history of palpitations,
arrhythmias, or syncope should be prioritized.
3. Follow-up clinical assessment is indicated in young
family members of SUDS victims who may manifest
symptoms and/or sign of the disease at an older age
and in all family members whenever additional
SUDS or SUDI events occur.
Class
IIa
4. Evaluation of ﬁrst-degree relatives of SUDS victims
with ambulatory and signal-averaged ECGs, cardiac
MRI, and provocative testing with Class Ic
antiarrhythmic drugs can be useful.
Class
IIb
5. Evaluation of ﬁrst-degree relatives of SUDS victims
with epinephrine infusion may be considered.
Expert Consensus Recommendations on SUDI Diagnosis
1. It is recommended that unexplained sudden death occurring
in an individual younger than 1 year of age with negative
pathological and toxicological assessment is termed “sudden
unexplained death in infancy” (SUDI).
Expert Consensus Recommendations on SUDI Evaluation
Class I 1. It is recommended that personal/family history and
circumstances of the sudden death are collected for
all SUDI victims.
2. Collection of blood and/or suitable tissue for
molecular autopsy is recommended in all SUDI
victims.
Class
IIa
3. An arrhythmia syndrome-focused molecular
autopsy/postmortem genetic testing can be useful
for all SUDI victims.
Class
IIb
4. Sudden death victims diagnosed with SUDI at
autopsy may be considered for assessment by an
expert cardiac pathologist to rule out the presence of
microscopic indicators of structural heart disease.
Expert Consensus Recommendations on SUDI Therapeutic
Interventions
Class I 1. Genetic screening of the ﬁrst-degree relatives of a
SUDI victim is recommendedwhenever a pathogenic
mutation in a gene associated with increased risk of
sudden death is identiﬁed by molecular autopsy in
the SUDI victim. Obligate mutation carriers should
be prioritized.
Class
IIa
2. Evaluation of ﬁrst-degree relatives of SUDI victims
with a family history of inherited heart disease or
other SUDS or SUDI deaths with resting ECG and
exercise stress testing and additional tests as
indicated can be useful. Assessment of ﬁrst-degree
relatives with the history of arrhythmias or syncope
should be prioritized.
3. Follow-up clinical assessment can be useful in
young family members of SUDI victims with a family
history of inherited heart disease or other SUDS or
SUDI death who may manifest symptoms and/or
signs of the disease at an older age and in all family
members whenever additional SUDS or SUDI
events occur.
Class
IIb
4. Evaluation of ﬁrst-degree relatives of SUDI victims
with resting ECG and exercise stress testing may be
considered.
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Deﬁnitions
An unexplained SCD is a pathological diagnosis of exclusion
that covers a number of possible etiologies. A commonly used
term is “sudden arrhythmic death syndrome” (SADS) that
describes an SCD where an autopsy and toxicology have been
undertaken, noncardiac etiologies excluded, and the heart found
to be morphologically normal.117,118 Another similar descriptor
“sudden adult death syndrome”119 has been termed to describe
nonpediatric cases. In Southeast Asia, cases of young male sudden
deaths have been attributed to “sudden unexpected or unexplained
death syndrome” (SUDS) as well as “sudden unexpected nocturnal
death syndrome” (SUNDS). These have, however, been directly
related to BrS as an etiology, have been used interchangeably, and
do not necessarily imply a thorough pathological evaluation.120
The terms “sudden infant death syndrome” (SIDS) and “sudden
unexpected death in infancy” (SUDI) are used in cases younger
than 1 year when the cause of death remains unexplained,
although SIDS implies a more stringent circumstantial and forensic
investigation. These are discussed further below.121
Epidemiology
The incidence of unexplained SCD among the general
population aged 4–64 years has been estimated to be up to
1.34/100,000 per annum,118 with 4.1% of the SCD cases in the
16–64 age group being unexplained.119 A recent Irish study
reported an incidence of unexplained SCD of 0.76/100,000 year
in subjects aged 14–35 years, accounting for 27% of the total
incidence of SCD.122
The incidence of unexplained sudden death below 1 year of age
(SIDS and SUDI) is well deﬁned and exceeds the incidence of SCD
in young adults or in children older than 1 year by an order of
magnitude. A recent national study from Ireland revealed a sudden
death rate of 1.4/100,000 among children aged 1–4 years com-
pared to 59/100,000 among children younger than 1 year.123
Campaigns to avoid modiﬁable risk factors (predominantly avoid-
ing the prone sleeping position) have resulted in signiﬁcant
declines in SIDS rates around the world. However, these have
plateaued and the current rate of SIDS in the United States is 53/
100,000.124
Figure 3. Algorithm to describe the investigative strategy for the identiﬁcation of inherited heart disease in families that have suffered a SUDS event.
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Diagnosis
The diagnosis of an unexplained SCD ideally relies on an
autopsy, and toxicological studies are undertaken to exclude
noncardiac etiologies. Further pathological evaluation of the heart
is then necessary with detailed histopathological examination to
exclude clear causes for SCD.125 This may identify structural
cardiac genetic disease such as hypertrophic cardiomyopathy that
would indicate the need for familial evaluation and the retention
of tissue suitable for DNA extraction and targeted genetic testing. If
the death remains unexplained, then additional investigations
may prove helpful (see Figure 3).
Screening of family members
When ﬁrst-degree relatives of victims of SADS or premature
unexplained sudden death undergo cardiac assessment, up to half
of families reveal cardiac genetic diseases such as inherited
arrhythmia syndromes or subtle forms of cardiomyopathy.117,126–
128 If an autopsy has not been undertaken, then additional
etiologies diagnosed in families include cardiomyopathies in gen-
eral and familial hypercholesterolemia.126,127 The strategy for
evaluation is often staged with less invasive investigations ﬁrst
and then more invasive tests if a diagnosis is not made, and it is
described in Figure 3.
The investigation of family members of cases of SUDI deaths
often occurs on an ad hoc basis, yet there are little data on its yield.
Molecular autopsy identiﬁes a lower burden of ion channel disease
in SIDS compared to SUDS, and there is a greater likelihood of
sporadic genetic disease as a cause of sudden death in infancy. It is
therefore likely that the yield of clinical evaluation of ﬁrst-degree
relatives will be signiﬁcantly lower than in SUDS. Nonetheless, if
there is a positive molecular autopsy result, a family history of
other cases of SUDI, SUDS, or premature unexplained sudden
death or of inherited heart disease, then the yield is likely to be
greater and familial evaluation more worthwhile.
10. Inherited Arrhythmia Clinics
Expert Consensus Recommendations on Inherited Arrhythmia
Clinics
Class
I
3. Patients (probands) and ﬁrst-degree relatives with a
diagnosed or suspected inherited cardiovascular
disease as a potential cause of SCD (SUDS/SUDI)
should be evaluated in a dedicated clinic with
appropriately trained staff
The evaluation and treatment of families suspected of having
inherited arrhythmias requires a multidisciplinary team and
approach. The presentation is often that of a proband or family
member who has experienced a life-threatening arrhythmia,
sudden cardiac arrest, or SCD. In the usual circumstances, there
are profound and far-reaching medical and psychosocial implica-
tions of both presentation of the inherited arrhythmia and genetic
testing on patients and families.1,2
Recent evidence suggests that a structured inherited arrhyth-
mia (or inherited cardiovascular disease) clinic improves the
likelihood of making a diagnosis in suspected cases of inherited
arrhythmias and SCD.126,128–132 The promise of an appropriately
resourced, structured clinic is that of a comprehensive evaluation
of patients and families, more efﬁcient use of diagnostic testing
and therapy and ready access to a broad range of medical, genetics,
and psychosocial expertise in managing families afﬂicted by
inherited arrhythmias. An inherited cardiovascular disease clinic
is an invaluable resource to patients and families not only at the
time of the initial evaluation but also in an ongoing fashion as
medical, genetic, and social questions relevant to the inherited
heart disease arise.
Figure 4. Workﬂow and personnel in the evaluation of patients and families with inherited arrhythmias.
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There are different operational models for inherited arrhythmia
clinics; the choice may be determined by the health system or the
regulations that exist in a given country. The personnel and workﬂow
in an ideal inherited arrhythmia clinic is illustrated schematically in
Figure 4. The key personnel include a clinic coordinator who is
responsible for patient intake, collection and collation of medical
records, scheduling appointments for patients and family members,
and assisting with questions relating to insurance coverage. The
physicians are typically a clinical cardiologist/electrophysiologist with
expertise in inherited arrhythmias and medical genetics or a medical
geneticist with an interest in cardiac arrhythmias partnering with a
clinical electrophysiologist. If the inherited arrhythmia clinic is part of
a larger program in inherited heart disease, experts in cardiomyopathy
will likely be available; otherwise access to such experts is essential.
The increasing complexity and demands of the proper diagnosis
and management of patients with inherited cardiovascular disease
creates an opportunity for the development of specialized training
for clinical electrophysiologists interested in the care of patients
with inherited arrhythmias.133 Such a specialty track would con-
solidate aspects of care involving indications and interpretation of
genetic test results and pharmacological and device therapy.
The management of patients with inherited arrhythmias includes
expert judgment regarding the indications, type, and interpretation of
genetic testing. In collaboration with a genetic counselor, patients and
families should be properly prepared regarding expectations and
outcomes of genetic testing. Arguably the most important part of
the testing procedure is reviewing the test results and implications
with patient and family, with counselor being prepared to discuss the
implications for other family members, the meaning of variants of
uncertain signiﬁcance, mosaicism, and issues related to paternity and
consanguinity. The genetic counselor is an essential134 and, in some
countries, legally mandated provider in this aspect of the care of
patients and families with suspected inherited arrhythmias.
The treatment of patients with inherited arrhythmias may vary
from medication therapy and lifestyle modiﬁcation to device
implantation to LCSD. Patients may require invasive EPS and
treatment with pacemakers or ICDs.
Patients in an inherited arrhythmia clinic may be survivors of
sudden cardiac arrest. The management of the recovery of these
patients from their index event may require the expertise of
psychologists and psychiatrists, and the intervention of physical
and occupational therapists. Moreover, the diagnosis of an inher-
ited disease of any kind, particularly one that carries with it the
risk of signiﬁcant morbidity and premature mortality, is often
associated with signiﬁcant emotional distress that at times will
require referral of patients and families.135–141
A structured inherited arrhythmia (or heart disease) clinic
provides the platform for optimized multidisciplinary evaluation
and management of patients and families with suspected inher-
ited heart disease. The collective efforts of the core staff and access
to a variety of experts in related disciplines will result in improved
quality of care,128,131,139,142–147 patient satisfaction,138 and
improvement in the appropriate use of diagnostic testing126,130
and therapeutic intervention. The promise of such a clinic struc-
ture is lower overall cost and improvement in patient outcomes.
Appendix A
See Tables A1 and A2.
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